[{"address1": "Building C14", "address2": "4th Floor No. 218, Xinghu Street Suzhou Industrial Park", "city": "Suzhou", "zip": "215123", "country": "China", "phone": "86 512 8777 3632", "website": "https://www.adagene.com", "industry": "Biotechnology", "industryKey": "biotechnology", "industryDisp": "Biotechnology", "sector": "Healthcare", "sectorKey": "healthcare", "sectorDisp": "Healthcare", "longBusinessSummary": "Adagene Inc., a clinical stage biotechnology company, engages in the research, development, and production of monoclonal antibody drugs for cancers in the People's Republic of China. Its lead product candidate is the ADG126, a masked fully-human anti-CTLA-4 mAb which is in phase 1b/2 clinical development for the treatment of cancer. The company also develops ADG116, a fully human anti-CTLA-4 antibody generated using NEObody technology, which is in phase 1b/2 clinical trials to treat advanced/metastatic solid tumors; ADG206, which is in phase 1 clinical development to treat advanced metastatic solid tumors; ADG104, anti-PD-L1 monoclonal antibody which is in phase 2 clinical development; and ADG125, a novel anti-CSF-1R mAb which is in Phase 2 clinical development. In addition, it is developing ADG138, a HER2xCD3 POWERbody which is in pre clinical trial to treat low expressing tumors, as well as resistant/refractory tumors; ADG152, a CD20xCD3 POWERbody which is in preclincal trial to treat off-tumor toxicities; ADG153, a masked anti-CD47 IgG1 SAFEbody, wihx is in preclinical trial for the treatment of hematologic and solid tumor; and CD28 T-cell engagers, an anti-CD28 bispecific POWERbody TCEs to treat solid tumors. The company was incorporated in 2011 and is headquartered in Suzhou, China.", "fullTimeEmployees": 138, "companyOfficers": [{"maxAge": 1, "name": "Dr. Peter P.  Luo Ph.D.", "age": 59, "title": "Co- Founder, Chairman, CEO and President of R&D", "yearBorn": 1966, "exercisedValue": 0, "unexercisedValue": 0}, {"maxAge": 1, "name": "Mr. Man Kin  Tam M.B.A.", "age": 48, "title": "CFO & Director", "yearBorn": 1977, "exercisedValue": 0, "unexercisedValue": 0}, {"maxAge": 1, "name": "Ms. Ling  Zhou", "title": "Executive Director & Head of Human Resources", "exercisedValue": 0, "unexercisedValue": 0}, {"maxAge": 1, "name": "Dr. Qinghai  Zhao Ph.D.", "age": 64, "title": "Chief Manufacturing Officer", "yearBorn": 1961, "exercisedValue": 0, "unexercisedValue": 0}, {"maxAge": 1, "name": "Ms. Yan  Li M.B.A.", "age": 50, "title": "Senior Vice President of Bioinformatics & Information Technology", "yearBorn": 1975, "exercisedValue": 0, "unexercisedValue": 0}, {"maxAge": 1, "name": "Ms. Xiaohong  She", "age": 58, "title": "Senior VP & Head of Clinical Operations", "yearBorn": 1967, "exercisedValue": 0, "unexercisedValue": 0}, {"maxAge": 1, "name": "Dr. Guizhong  Liu Ph.D.", "age": 54, "title": "Senior Vice President of Early Drug Discovery", "yearBorn": 1971, "exercisedValue": 0, "unexercisedValue": 0}, {"maxAge": 1, "name": "Mr. Alexander  Goergen", "age": 38, "title": "VP & Head of Business Development", "yearBorn": 1987, "exercisedValue": 0, "unexercisedValue": 0}, {"maxAge": 1, "name": "Dr. Jiping  Zha M.D., Ph.D.", "title": "Executive Vice President of Clinical Development", "exercisedValue": 0, "unexercisedValue": 0}, {"maxAge": 1, "name": "Dr. Songmao  Zheng Ph.D.", "title": "Senior VP of Clinical Pharmacology & Quantitative Sciences", "exercisedValue": 0, "unexercisedValue": 0}], "executiveTeam": [], "maxAge": 86400, "priceHint": 4, "previousClose": 3.24, "open": 3.185, "dayLow": 3.08, "dayHigh": 3.3712, "regularMarketPreviousClose": 3.24, "regularMarketOpen": 3.185, "regularMarketDayLow": 3.08, "regularMarketDayHigh": 3.3712, "payoutRatio": 0.0, "beta": 0.727, "forwardPE": -4.361111, "volume": 64002, "regularMarketVolume": 64002, "averageVolume": 179845, "averageVolume10days": 137160, "averageDailyVolume10Day": 137160, "bid": 3.04, "ask": 3.37, "bidSize": 1, "askSize": 1, "marketCap": 147992192, "fiftyTwoWeekLow": 1.3, "fiftyTwoWeekHigh": 3.3712, "allTimeHigh": 31.83, "allTimeLow": 0.9, "priceToSalesTrailing12Months": 1433.9773, "fiftyDayAverage": 2.13308, "twoHundredDayAverage": 1.97364, "trailingAnnualDividendRate": 0.0, "trailingAnnualDividendYield": 0.0, "currency": "USD", "tradeable": false, "enterpriseValue": 129012008, "profitMargins": 0.0, "floatShares": 32936510, "sharesOutstanding": 47131270, "sharesShort": 62815, "sharesShortPriorMonth": 23778, "sharesShortPreviousMonthDate": 1767139200, "dateShortInterest": 1769731200, "sharesPercentSharesOut": 0.0013, "heldPercentInsiders": 0.15511, "heldPercentInstitutions": 0.28632998, "shortRatio": 0.32, "shortPercentOfFloat": 0.0016, "impliedSharesOutstanding": 47131270, "bookValue": 0.804, "priceToBook": 3.9054728, "lastFiscalYearEnd": 1735603200, "nextFiscalYearEnd": 1767139200, "mostRecentQuarter": 1751241600, "netIncomeToCommon": -29889636, "trailingEps": -0.64, "forwardEps": -0.72, "enterpriseToRevenue": 1250.068, "enterpriseToEbitda": -3.937, "52WeekChange": 0.70157063, "SandP52WeekChange": 0.11527538, "quoteType": "EQUITY", "currentPrice": 3.14, "targetHighPrice": 9.0, "targetLowPrice": 7.0, "targetMeanPrice": 8.0, "targetMedianPrice": 8.0, "recommendationMean": 1.33333, "recommendationKey": "strong_buy", "numberOfAnalystOpinions": 5, "totalCash": 62828156, "totalCashPerShare": 1.066, "ebitda": -32765248, "totalDebt": 6849932, "quickRatio": 2.203, "currentRatio": 2.292, "totalRevenue": 103204, "debtToEquity": 18.068, "revenuePerShare": 0.002, "returnOnAssets": -0.24893999, "returnOnEquity": -0.63259, "grossProfits": 103204, "freeCashflow": -17171550, "operatingCashflow": -27456540, "grossMargins": 1.0, "ebitdaMargins": 0.0, "operatingMargins": -322.83603, "financialCurrency": "USD", "symbol": "ADAG", "language": "en-US", "region": "US", "typeDisp": "Equity", "quoteSourceName": "Nasdaq Real Time Price", "triggerable": true, "customPriceAlertConfidence": "HIGH", "epsTrailingTwelveMonths": -0.64, "epsForward": -0.72, "epsCurrentYear": -0.65, "priceEpsCurrentYear": -4.8307695, "fiftyDayAverageChange": 1.0069201, "fiftyDayAverageChangePercent": 0.47204986, "twoHundredDayAverageChange": 1.1663601, "twoHundredDayAverageChangePercent": 0.590969, "sourceInterval": 15, "exchangeDataDelayedBy": 0, "ipoExpectedDate": "2021-02-09", "averageAnalystRating": "1.3 - Strong Buy", "cryptoTradeable": false, "corporateActions": [], "postMarketTime": 1771621804, "regularMarketTime": 1771621202, "exchange": "NGM", "messageBoardId": "finmb_118162960", "exchangeTimezoneName": "America/New_York", "exchangeTimezoneShortName": "EST", "gmtOffSetMilliseconds": -18000000, "market": "us_market", "esgPopulated": false, "hasPrePostMarketData": true, "firstTradeDateMilliseconds": 1612881000000, "shortName": "Adagene Inc.", "longName": "Adagene Inc.", "regularMarketChangePercent": -3.08642, "regularMarketPrice": 3.14, "marketState": "CLOSED", "postMarketChangePercent": 0.0, "postMarketPrice": 3.14, "postMarketChange": 0.0, "regularMarketChange": -0.0999999, "regularMarketDayRange": "3.08 - 3.3712", "fullExchangeName": "NasdaqGM", "averageDailyVolume3Month": 179845, "fiftyTwoWeekLowChange": 1.8400002, "fiftyTwoWeekLowChangePercent": 1.4153848, "fiftyTwoWeekRange": "1.3 - 3.3712", "fiftyTwoWeekHighChange": -0.23119998, "fiftyTwoWeekHighChangePercent": -0.06858091, "fiftyTwoWeekChangePercent": 70.15707, "earningsTimestampStart": 1753268340, "earningsTimestampEnd": 1753704000, "isEarningsDateEstimate": true, "displayName": "Adagene", "trailingPegRatio": null, "__fetch_time": "2026-02-21"}]